Bayer Reports P-III (OCEANIC-STROKE) Trial Data on Asundexian for Secondary Stroke Prevention

Shots: The P-III (OCEANIC-STROKE) trial assessed asundexian (50mg, QD, PO) vs PBO, both in combination with antiplatelet therapy, in pts (n=12,327) for prevention of ischemic stroke after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack Trial showed a 26% reduction in recurrent ischemic stroke without increased ISTH major bleeding across all subgroups, met key…

ByRidhi RastogiFebruary 6, 2026

NEWS

Eisai and Henlius Partner to Commercialize Serplulimab in Japan

Shots: Eisai & Henlius have entered into an exclusive commercialization & co-exclusive development & manufacturing license agreement for serplulimab (Hetronifly in the EU) in Japan As per the deal, Eisai will obtain exclusive rights to commercialize serplulimab in Japan in exchange for $75M upfront, ~$80.01M in regulatory milestones, ~$233.3M in sales milestones, with double-digit royalties…

ByRidhi RastogiFebruary 6, 2026

NEWS

Boehringer Ingelheim Secures US FDA’s EUA for Ivomec (ivermectin) to Prevent New World Screwworm Infestations in Cattle

Shots: The US FDA has granted Emergency Use Authorization for the use of Ivomec (ivermectin) 1% Injection for the prevention of infestations caused by New World screwworm (NWS) in cattle Under the EUA, Ivomec is authorized for NWS prevention when administered within 24hrs. of birth, at castration, or upon wound appearance, with specific exclusions for…

ByRidhi RastogiFebruary 6, 2026

NEWS

Hims & Hers Launches Multi-Cancer Blood Test by Galleri

Shots: Hims & Hers Health has launched access to the Multi-Cancer Test by Galleri, offering a simple blood test for early cancer screening The Hims & Hers Multi-Cancer Test by Galleri detects a shared signal from 50+ cancers, incl. those without recommended screenings, & can be taken annually to help identify cancers early, often before…

ByRidhi RastogiFebruary 5, 2026

NEWS

Evogene and Shanghai Lishan Biopharmaceuticals Partner for BMC128

Shots: Biomica (Evogene’s subsidiary) & Shanghai Lishan Biopharmaceuticals have entered into an exclusive worldwide licensing agreement for BMC128, currently in P-I trial As per the deal, Lishan Biotech will receive exclusive rights to develop, manufacture, & commercialize BMC128, with Biomica receiving development milestone payments & royalties on future commercial sales Lishan Biotech is planning to…

ByRidhi RastogiFebruary 5, 2026

NEWS

Alvotech Reveals PK Data on AVT80 (Biosimilar, Entyvio)

Shots: Alvotech reported positive top-line data from the AVT80-GL-P01 PK study comparing AVT80 with Entyvio in healthy adults The study met all 1EP, demonstrating PK similarity between AVT80 & Entyvio following a single 108mg/0.68mL SC dose, supporting AVT80’s biosimilar profile Alvotech is developing AVT16 (IV) & AVT80 (SC) as Entyvio’s biosimilars, with the AVT80-GL-P01 study…

ByRidhi RastogiFebruary 5, 2026

NEWS

PrimeGen US to Go Public via DT Cloud Star Acquisition Corporation’s SPAC Deal

Shots: PrimeGen US has entered into a definitive business combination agreement with DT Cloud Star at an implied equity value of ~$1.5B, with closing expected in H2’26 After closing, the combined entity is expected to operate as PrimeGen US or a successor company & will be listed on Nasdaq under a new ticker symbol PrimeGen…

ByRidhi RastogiFebruary 5, 2026

NEWS

Daiichi Sankyo Reports First Patient Dosing in P-I/II Trial of DS3790 for R/R B-Cell Non-Hodgkin Lymphoma

Shots: Daiichi Sankyo has dosed the first patient with DS3790 in the P-I/II trial for pts with r/r B-cell non-Hodgkin lymphoma The trial will assess DS3790 in ~420 pts with r/r B-cell NHL, evaluating safety endpoints as well as efficacy endpoints incl. overall response, DCR, DoR, time to response, PFS, & OS DS3790 is a…

ByRidhi RastogiFebruary 5, 2026

NEWS

Hologic’s Aptima HPV Assay Receives the US FDA Approval for HPV Primary Screening

Shots: The US FDA has approved AptimaHPV Assay, an mRNA-based assay for clinician-collected HPV primary screening Approval follows completion of a real-world HPV screening study of 650,000+ women across US, showing the Aptima HPV Assay has clinically comparable sensitivity to an FDA-approved DNA-based HPV test & is effective for detecting CIN2+ & CIN3+ in primary…

ByRidhi RastogiFebruary 5, 2026

NEWS

ZipBio and MeiraGTx Partner to Advance AAV Gene Therapy for Geographic Atrophy

Shots: ZipBio has entered into an exclusive license agreement with MeiraGTx, granting MeiraGTx exclusive right to AAV gene therapy to treat Geographic Atrophy Licensing deal will combine MeiraGTx’s expertise in vector design, clinical development, & in-house genetic medicine manufacturing with ZipBio’s de novo protein therapeutics created using its COMPACT generative AI platform As per the…

ByRidhi RastogiFebruary 4, 2026

Ridhi Rastogi

Bayer Reports P-III (OCEANIC-STROKE) Trial Data on Asundexian for Secondary Stroke Prevention

Eisai and Henlius Partner to Commercialize Serplulimab in Japan

Boehringer Ingelheim Secures US FDA’s EUA for Ivomec (ivermectin) to Prevent New World Screwworm Infestations in Cattle

Hims & Hers Launches Multi-Cancer Blood Test by Galleri

Evogene and Shanghai Lishan Biopharmaceuticals Partner for BMC128

Alvotech Reveals PK Data on AVT80 (Biosimilar, Entyvio)

PrimeGen US to Go Public via DT Cloud Star Acquisition Corporation’s SPAC Deal

Daiichi Sankyo Reports First Patient Dosing in P-I/II Trial of DS3790 for R/R B-Cell Non-Hodgkin Lymphoma

Hologic’s Aptima HPV Assay Receives the US FDA Approval for HPV Primary Screening

ZipBio and MeiraGTx Partner to Advance AAV Gene Therapy for Geographic Atrophy

Contact US

FOLLOW US